Plain-English translation of NCT07449091 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers want to understand whether people with hepatitis B who take antiviral medications like TAF or TDF become truly non-infectious. The study will compare virus levels in blood and body fluids across four groups: people on long-term treatment, untreated people with high or low virus levels, people who have cleared the infection, and healthy uninfected people. The goal is to gather evidence that could reduce stigma and fear around hepatitis B transmission.
Many people with hepatitis B experience anxiety, shame, and social isolation because of fears about infecting their partners and loved ones. If research can confirm that taking this medication consistently makes the virus undetectable and truly non-transmissible—similar to what has been shown with HIV—it could dramatically reduce that fear and help people feel safer in their relationships.
You likely qualify if…
You likely don't qualify if…
You would visit the research site to provide blood and body fluid samples so researchers can measure virus levels. The study compares these samples across different groups of people—those on antiviral medication, those not on medication, those who have recovered, and healthy controls. Your participation helps answer an important question: does taking hepatitis B medication consistently make the virus truly non-transmissible, which could change how people understand their risk to partners and loved ones.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States
Sponsor
NYU Langone Health
Collaborators
Gilead Sciences
Enrollment target
~55 participants
Started
May 2026
Primary completion
September 2027
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
AnnMarie Liapakis, MD
NYU Langone Health
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.